Characteristics of IFIs during VEN-HMA therapy
| UPN . | Age, y/sex . | AML setting . | AML type . | Antifungal prophylaxis . | Response . | Prior alloHCT . | HMA regimen (d) . | Onset of IFI, d . | Diagnosis of IFI . | Fungal infection . | Site . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 77/M | Untreated | De novo | None | CR | No | Azacitidine (7) | 281 | Probable | Aspergillus niger | Lung |
| 2 | 68/F | r/r | Therapy related | Micafungin | CR | No | Decitabine (5) | 35 | Proven | Mucor | Disseminated; lung, erector spinae muscles, liver and spleen. |
| 3 | 75/M | r/r | De novo | Fluconazole | CRi | No | Decitabine (5) | 104 | Proven | Rhizopus spp. | Sinusitis and brain infarct |
| 4 | 70/M | r/r | De novo | Micafungin | CRi | No | Azacitidine (7) | 109 | Probable and proven | Aspergillus Mucor - 11/2018 developed on CRESEMBA then treated with AmBisome | Lung liver/spleen, had splenectomy. |
| 5 | 55/F | r/r | Secondary | Posaconazole | Refractory | Yes | Decitabine (5) | 56 | Proven | Scedosporium prolificans | Blood |
| 6 | 62/M | r/r | De novo | Micafungin | Refractory | No | Decitabine (10) | 92 | Probable | Aspergillus | Lung |
| 7 | 66/M | Untreated | De novo | Micafungin (patient was being treated with ABELCET empirically when BALF from 8/9/2017 was positive for hyphae) | Refractory | No | Decitabine (5) | 61 | Probable | Unspecified mold infection | Lung |
| 8 | 57/M | r/r | Secondary | Micafungin | Refractory | No | Decitabine (10) | 38 | Probable | Aspergillus | Lung |
| 9 | 45/M | Untreated | Therapy related | Isavuconazonium | Refractory | No | Decitabine (10) | 71 | Proven | Rhizopus spp. | Sinus/orbit |
| 10 | 32/F | r/r | De novo | Posaconazole | Refractory | Yes | Decitabine (10) | 73 | Probable | Aspergillus | Lung |
| 11 | 74/F | r/r | De novo | None | Refractory | No | Azacitidine (7) | 60 | Proven | Scedosporium apiospermum | Skin/deep tissue |
| 12 | 71/F | r/r | Secondary | Isavuconazonium | Refractory | No | Azacitidine (7) | 115 | Probable | Mucor | Lung |
| 13 | 56/F | r/r | De novo | Posaconazole | Refractory | Yes | Azacitidine (7) | 59 | Probable | Aspergillus | Lung |
| 14 | 68/M | r/r | Secondary | Isavuconazonium | Refractory | No | Decitabine (5) | 89 | Proven | Aspergillus fumigatus | Lung |
| 15 | 55/F | r/r | Therapy related | Micafungin | Refractory | No | Decitabine (10) | 43 | Probable | Penicillium spp. | Lung |
| UPN . | Age, y/sex . | AML setting . | AML type . | Antifungal prophylaxis . | Response . | Prior alloHCT . | HMA regimen (d) . | Onset of IFI, d . | Diagnosis of IFI . | Fungal infection . | Site . |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 77/M | Untreated | De novo | None | CR | No | Azacitidine (7) | 281 | Probable | Aspergillus niger | Lung |
| 2 | 68/F | r/r | Therapy related | Micafungin | CR | No | Decitabine (5) | 35 | Proven | Mucor | Disseminated; lung, erector spinae muscles, liver and spleen. |
| 3 | 75/M | r/r | De novo | Fluconazole | CRi | No | Decitabine (5) | 104 | Proven | Rhizopus spp. | Sinusitis and brain infarct |
| 4 | 70/M | r/r | De novo | Micafungin | CRi | No | Azacitidine (7) | 109 | Probable and proven | Aspergillus Mucor - 11/2018 developed on CRESEMBA then treated with AmBisome | Lung liver/spleen, had splenectomy. |
| 5 | 55/F | r/r | Secondary | Posaconazole | Refractory | Yes | Decitabine (5) | 56 | Proven | Scedosporium prolificans | Blood |
| 6 | 62/M | r/r | De novo | Micafungin | Refractory | No | Decitabine (10) | 92 | Probable | Aspergillus | Lung |
| 7 | 66/M | Untreated | De novo | Micafungin (patient was being treated with ABELCET empirically when BALF from 8/9/2017 was positive for hyphae) | Refractory | No | Decitabine (5) | 61 | Probable | Unspecified mold infection | Lung |
| 8 | 57/M | r/r | Secondary | Micafungin | Refractory | No | Decitabine (10) | 38 | Probable | Aspergillus | Lung |
| 9 | 45/M | Untreated | Therapy related | Isavuconazonium | Refractory | No | Decitabine (10) | 71 | Proven | Rhizopus spp. | Sinus/orbit |
| 10 | 32/F | r/r | De novo | Posaconazole | Refractory | Yes | Decitabine (10) | 73 | Probable | Aspergillus | Lung |
| 11 | 74/F | r/r | De novo | None | Refractory | No | Azacitidine (7) | 60 | Proven | Scedosporium apiospermum | Skin/deep tissue |
| 12 | 71/F | r/r | Secondary | Isavuconazonium | Refractory | No | Azacitidine (7) | 115 | Probable | Mucor | Lung |
| 13 | 56/F | r/r | De novo | Posaconazole | Refractory | Yes | Azacitidine (7) | 59 | Probable | Aspergillus | Lung |
| 14 | 68/M | r/r | Secondary | Isavuconazonium | Refractory | No | Decitabine (5) | 89 | Proven | Aspergillus fumigatus | Lung |
| 15 | 55/F | r/r | Therapy related | Micafungin | Refractory | No | Decitabine (10) | 43 | Probable | Penicillium spp. | Lung |
BALF, bronchoalveolar lavage fluid; F, female; M, male; UPN, unique patient number.